CRNX - Crinetics Pharmaceuticals, Inc.
IEX Last Trade
53.89
1.150 2.134%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:15:24 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$52.74
1.15
2.18%
Fundamental analysis
11%
Profitability
8%
Dept financing
3%
Liquidity
75%
Performance
0%
Performance
5 Days
0.63%
1 Month
-3.83%
3 Months
6.92%
6 Months
20.21%
1 Year
50.21%
2 Year
230.51%
Key data
Stock price
$53.89
DAY RANGE
$52.74 - $53.35
52 WEEK RANGE
$34.89 - $62.53
52 WEEK CHANGE
$48.27
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Scott R. Struthers
Region: US
Website: crinetics.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: crinetics.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Crinetics Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism.
Recent news